The Luminesce Alliance is a world-leading paediatric research co-operative, established to harness the strengths of its partner organisations to unlock future prevention, treatments and ultimately, cures, for childhood illnesses. In 2022, the primary focus of the Company was delivering the Centre for Paediatric Precision Medicine research programs that were established with a $20 million investment from NSW Government. The Centre for Paediatric Precision Medicine supported NSW s Paediatric Precision Medicine (PPM) Program which consisted of ten innovative and translational research projects delivered through the Alliance. In addition to this program, there were a further eight NSW Government funded research programs managed and delivered across the Luminesce Alliance they include: Establishment of smallscale cGMP vector manufacturing for gene and cell therapy clinical trials. INFORM2: An exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with highrisk Malignancies. Newborn Screening Program Pilot for SMA and PID in NSW & ACT; A selfamplifying theranostic for treatment of neuroblastoma. Curing genetic metabolic liver disease by precise genomic and epigenomic editing. Translating disease severity biomarkers into the clinic for Rett syndrome. Precision medicine addressing a novel disease pathway to preserve sight in retinal dystrophies. LA Centre for RNA Diagnostics: A pipeline of accredited RNA Diagnostics to extend diagnostic yield of rare disorders by 25 % in 5 years.